scm logo

SCM Life Science (SCM Life Science, 298060, CEO Lee Byung-gun), a company specializing in research and development of cell therapy, announced on the 25th that a paper related to clinical trials for the treatment of atopic dermatitis stem cell therapy conducted before commercialization was published in The Journal of Dermatology, an international journal in dermatology. Currently, SCM Life Science is conducting a phase 2 clinical trial for commercialization of "SCM-AGH," a stem cell treatment for atopic dermatitis. 

The paper listed in the Journal of Dermatology contains the results of a clinical trial conducted by Choi Kwang-sung, a dermatologist at Inha University Hospital, a research director at ADT2002, a clinical trial for atopic dermatitis. According to the results of clinical trials, 4 out of 5 patients showed a therapeutic effect of improving their efficacy evaluation score by more than 50%, of which 2 patients maintained the therapeutic effect of stem cell therapy for more than 3 years and 2 years, respectively. This long-term effect can be said to be the biggest differentiation compared to other existing treatments, and as the participating patients were patients who did not see any improvement as existing treatments, it is said that it opened up the possibility of treatment in a new way.

The Journal of Dermatology, where the paper is listed, is considered an international journal with international authority in the field of dermatology officially published in cooperation with the Japanese Dermatology Association and the Asian Dermatology Association.

The results of clinical trials for this therapeutic purpose became the cornerstone of a phase 1 clinical trial of SCM-AGH, an atopic dermatitis stem cell treatment completed by Scm Life Science in December last year. In phase 1 clinical trials, SCM-AGH showed a therapeutic effect of improving efficacy evaluation scores by more than 50% in 13 of the 19 patients who participated in the clinical trial, 12 of the 13 patients confirmed long-term treatment effects, and the results of phase 1 clinical trials will be published in journals. SCM Life Science launched a phase 2 clinical trial on SCM-AGH in February.

An official from Scm Life Science said, The clinical results, which were the basis of Scm Life Science' clinical trials for atopic dermatitis, were registered in international journals and recognized for their objective value. and "we think the results of the ongoing phase 2 clinical trial can also be expected to be positive."